9961:HKEXTrip.com Group Ltd. Analysis
Data as of 2026-07-25 - not real-time
HK$342.60
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Trip.com is trading at HK$342.6, comfortably above its 20‑day SMA of HK$330.99 but still below the 50‑day SMA of HK$355.02, indicating a short‑term bounce within a broader bearish backdrop. The 200‑day SMA sits near HK$457, underscoring the long‑term downtrend flagged by the “bearish” trend direction flag. A neutral RSI of 49.8 suggests momentum is neither overbought nor oversold, while the MACD histogram is positive, giving a modest “bullish” signal despite the line itself remaining negative. Volatility is elevated at roughly 48% over the past 30 days and volume is on a decreasing trend, which together raise the short‑term risk profile. The stock’s beta of 0.60 points to lower systematic risk than the market, yet the recent max drawdown of nearly 50% highlights vulnerability to sharp corrections.
On the fundamentals side, revenue grew 17% year‑over‑year to HK$64.8 bn, and margins remain robust with gross margin above 80% and operating margin of 24%. Profitability is strong, delivering a profit margin of 48.6% and a ROE of 20%, while the balance sheet is cash‑rich (HK$81 bn) versus debt of HK$31 bn, resulting in a net‑cash position. The forward‑looking valuation is compelling: a trailing PE of 6.5 and forward PE of 10 translate to a target median price of HK$489, implying upside of roughly 42% from current levels. The dividend yield sits at a modest 0.58% with a payout ratio of 0, indicating that dividend sustainability is weak and investors should not rely on income. Recent material news includes an administrative penalty from China’s market regulator, adding a layer of regulatory uncertainty for the company’s domestic operations. Given the combination of undervaluation, strong cash flow generation and growth prospects, the medium‑term outlook favors accumulation, while the short‑term technical picture suggests caution. In the long run, the travel recovery tailwinds and resilient balance sheet support a bullish stance, provided regulatory and geopolitical risks remain contained.
On the fundamentals side, revenue grew 17% year‑over‑year to HK$64.8 bn, and margins remain robust with gross margin above 80% and operating margin of 24%. Profitability is strong, delivering a profit margin of 48.6% and a ROE of 20%, while the balance sheet is cash‑rich (HK$81 bn) versus debt of HK$31 bn, resulting in a net‑cash position. The forward‑looking valuation is compelling: a trailing PE of 6.5 and forward PE of 10 translate to a target median price of HK$489, implying upside of roughly 42% from current levels. The dividend yield sits at a modest 0.58% with a payout ratio of 0, indicating that dividend sustainability is weak and investors should not rely on income. Recent material news includes an administrative penalty from China’s market regulator, adding a layer of regulatory uncertainty for the company’s domestic operations. Given the combination of undervaluation, strong cash flow generation and growth prospects, the medium‑term outlook favors accumulation, while the short‑term technical picture suggests caution. In the long run, the travel recovery tailwinds and resilient balance sheet support a bullish stance, provided regulatory and geopolitical risks remain contained.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price above 20‑day SMA but below 50‑day SMA
- Decreasing volume and high 30‑day volatility
- Bearish long‑term trend despite modest MACD bullish signal
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth (17% YoY) and high margins
- Low trailing PE (6.5) versus target price implying ~42% upside
- Robust cash position offsetting moderate debt levels
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Secular recovery in travel demand and diversified service portfolio
- Sustainable profitability with ROE around 20% and high gross margin
- Undervalued valuation metrics combined with resilient balance sheet
Key Metrics & Analysis
Financial Health
Revenue Growth17.20%
Profit Margin48.65%
P/E Ratio6.5
ROE20.14%
ROA3.95%
Debt/Equity18.82
P/B Ratio1.2
Technical Analysis
TrendBearish
RSI49.8
SupportHK$299.20
ResistanceHK$356.00
MA 20HK$330.99
MA 50HK$355.02
MA 200HK$457.14
MACDBullish
VolumeDecreasing
Fear & Greed Index88.25
Valuation
Target PriceHK$486.21
Upside/Downside41.92%
GradeUndervalued
TypeBlend
Dividend Yield0.58%
Risk Assessment
Beta0.60
Volatility47.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.